Zhiwei Chen

机构：Shanghai Jiao Tong University, Huazhong Agricultural University, Wenzhou Medical University, XinHua Hospital, Shanghai Chest Hospital, Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Chongqing Medical University · ORCID：0009-0002-9068-4401

发表论文 33 篇 · 总被引 604 次 · h-index 13

代表论文

• The histone acetylranseferase h MOF acetylates Nrf 2 and regulates anti‐drug responses in human non‐small cell lung cancer (2014 · British Journal of Pharmacology · 被引 111)
• Dying tumor cells stimulate proliferation of living tumor cells via caspase‐dependent protein kinase Cδ activation in pancreatic ductal adenocarcinoma (2014 · Molecular Oncology · 被引 101)
• FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response (2014 · Nucleic Acids Research · 被引 37)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells (2020 · Biochemical Journal · 被引 20)
• Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial (2024 · Journal of Thoracic Oncology · 被引 19)